Navigation Links
MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium
Date:12/7/2011

.

About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology.  Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. 

Dune Medical Devices is a privately held company financed by Apax Partners since 2004.  It has offices in the U.S., Israel, Germany and Switzerland.  For more information, please visit www.dunemedical.com   

Contact:
Michael Graffeo
Dune Medical Devices
Michael.graffeo@dunemedical.com
(508) 620-2782


'/>"/>
SOURCE Dune Medical Devices
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
2. Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
3. ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514
4. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
5. EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System
6. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
7. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
8. First Patient Enrolled in SARcode Biosciences Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
9. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
10. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
11. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014  Low T Center endorses ... in Hyattsville, Maryland earlier ... the proper patient population for testosterone therapy (TRT), ... associated with TRT. Examining recent claims from studies that ... "available epidemiological studies do not provide convincing evidence ...
(Date:9/18/2014)... 18, 2014   MacPractice,s MacPractice MD MU ... EHR certification, which designates that the software is capable ... and Stage 2 Meaningful Use measures required to qualify ... (ARRA).  MacPractice MD MU version 5.0 was certified on ... Office of the National Coordinator-Authorized Certification Body (ONC-ACB) and ...
(Date:9/18/2014)... 2014 This BCC Research report discusses the medical device ... growth and size, and opportunities for different devices and regions. ... Patent analysis in the report focuses on technological trends in ... Europe and Japan . ... the global medical device technologies market. - Analyze market structure, ...
Breaking Medicine Technology:Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4
... , , , , NASHVILLE, Tenn. and ... find that 70 percent of surveyed pharmacy directors expect to ... of chronic pain. Tanezumab, which is expected to be the ... under medical supervision, will likely be covered as a medical ...
... , , , SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. ... ), Eli Lilly and Company (NYSE: LLY ) ... results from a head-to-head study comparing exenatide once weekly, an ... in patients with type 2 diabetes. After 24 weeks of ...
Cached Medicine Technology:Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 2Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7
(Date:9/19/2014)... Centre for Accident Research & Road Safety - Queensland ... in Transport Conference (OSIT) which is being held on ... Blackman, a CARRS-Q road safety researcher, said speed limit ... limits and related traffic controls remained in place at ... If people are asked to slow down at roadwork ...
(Date:9/19/2014)... Lifeinsure.biz has released a new ... can be purchased without medical examinations. , Life ... a life insurance policy more advantageous. Clients can read ... extra options available for a no medical exam life ... required is simple to purchase, however it is more ...
(Date:9/19/2014)... 19, 2014 Outsourcing services provider Profit By ... US IT conglomerate to provide HR outsourcing services in India. ... an exclusive partner and will act as a talent acquisition ... deploy over 120 personnel across 3 locations in India in ... , "This is a significant win for us and we ...
(Date:9/19/2014)... 2014 Kyrgyzstan has one of ... To reduce the burden of tuberculosis (TB) and ... Kyrgyz Republic, Abt Associates has been awarded the ... Program under a five-year cooperative agreement with total ... support universal and equitable access to high-quality TB ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:New Project Aims to Reduce Burden of Tuberculosis in the Kyrgyz Republic 2Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2
... disease, rheumatoid arthritis (RA) is characterized by persistent inflammation ... Beyond loss of mobility, sufferers face a high risk ... contributing to the development of RA, tumor necrosis factor ... Inhibition of TNFa has opened promising new treatment ...
... DALLAS Feb. 28, 2008 UT Southwestern Medical ... operation requiring only a single incision in the bellybutton ... It is the first such operation in North Texas. ... Homero Rivas, assistant professor of surgery, who completed the ...
... Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug Administration., The four products ... equivalent of,Bontril(R) tablets by Valeant Pharmaceuticals, are indicated ... of Phendimetrazine tartrate tablets,had annual sales of US$3.1 ...
... 40.6%, ETHEX Revenue Up 57.8% for Third Quarter, Up ... Revenue Up 16.6% for Third Quarter, Up 15.2% ... KV Pharmaceutical Company,(NYSE: KVa/KVb) today reported preliminary financial results ... 2008 ended December 31, 2007. The,results reflected continued acceleration ...
... the Robert Wood Johnson Foundation, has launched the Network for ... study health care disparities affecting minorities with chronic diseases. ... a new generation of researchers with an expertise in health ... to be directed by Dr. Michael Rodrguez, associate professor of ...
... drop in a severe form of the disorder, , , WEDNESDAY, Feb. ... decreasing, and a more severe form of the disease caused by ... Those are the two main findings from a Massachusetts study that ... and 35 babies a year before 2003 to less than 20 ...
Cached Medicine News:Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 2Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 3Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 2Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 3Health News:Actavis Extends Portfolio With Four New Products in the U.S. 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 3Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 4Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 5Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 6Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 7Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 8Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 9Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 10Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 11Health News:UCLA launches network to study health care disparities affecting minorities 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: